Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.49 and last traded at $20.45, with a volume of 506,942 shares traded. The stock had previously closed at $20.01.

A number of equities analysts recently issued reports on AMPH shares. Needham & Company LLC dropped their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Monday, August 1st. Jefferies Group upped their target price on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. BMO Capital Markets restated a “hold” rating and set a $17.00 target price on shares of Amphastar Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $22.00 target price on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 11th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Amphastar Pharmaceuticals has an average rating of “Buy” and an average price target of $19.83.

The company has a market cap of $920.92 million and a price-to-earnings ratio of 66.27. The stock’s 50-day moving average is $17.41 and its 200-day moving average is $14.28.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.22. During the same quarter in the previous year, the business earned ($0.09) EPS. The business earned $68 million during the quarter, compared to analysts’ expectations of $62.10 million. The business’s revenue for the quarter was up 26.4% on a year-over-year basis. On average, equities analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current fiscal year.

In other news, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $16.00, for a total transaction of $36,752.00. Following the transaction, the chief financial officer now owns 66,949 shares in the company, valued at $1,071,184. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard K. Prins sold 7,500 shares of the firm’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $15.94, for a total value of $119,550.00. Following the transaction, the director now owns 29,086 shares in the company, valued at approximately $463,630.84. The disclosure for this sale can be found here.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.